Unum Therapeutics Inc. | 200 Cambridge Park Drive Suite 3100 | Cambridge, MA 02140  USA

Tel. +1.617.945.5576 | Email: info@unumrx.com

  • LinkedIn - White Circle
  • Twitter - White Circle

© Copyright 2014-2019 Unum Therapeutics

Posters | Archives |

Archive Posters

The posters contained in this archive section are provided for historical purposes only. The information contained in each poster is accurate only as of the date each poster was originally issued. Unum disavows any obligation to update the information contained in such posters after the date of their issuance

2016 Posters

December 06, 2016

American Society of Hematology (ASH) 2016 Conference Posters:

A First-in-Human Study of Autologous T Lymphocytes with Antibody-Dependent Cell Cytotoxicity (ADCC) in Patients with B-Cell Non-Hodgkin Lymphoma (NHL) (Results from a Investigator Sponsored Trial conducted at National University Hospital and Singapore General Hospital using transiently-expressed ACTR in combination with Rituximab.)

ACTR platform as an adaptable, universal T cell therapy that can target multiple tumor antigens to overcome antigen escape

Targeting CD20+ Relapsed Refractory B Cell Lymphoma with ACTR087, Antibody Coupled T cell Receptor (ACTR) Engineered Autologous T cells, in Combination with Rituximab

October 26, 2016

American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy 2016 Meeting Posters:

Efficient Targeting of HER2 positive cancers by Antibody-Coupled T cell Receptor (ACTR) Engineered Autologous T cells

High throughput triage of the ACTR platform demonstrates broad activity across multiple tumor targets